230 related articles for article (PubMed ID: 21340507)
1. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J
Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507
[TBL] [Abstract][Full Text] [Related]
2. Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.
Wei CC; Ball S; Lin L; Liu A; Fuchs JR; Li PK; Li C; Lin J
Int J Oncol; 2011 Jan; 38(1):279-85. PubMed ID: 21109950
[TBL] [Abstract][Full Text] [Related]
3. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.
Couto JI; Bear MD; Lin J; Pennel M; Kulp SK; Kisseberth WC; London CA
BMC Vet Res; 2012 Dec; 8():244. PubMed ID: 23244668
[TBL] [Abstract][Full Text] [Related]
4. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.
Bid HK; Oswald D; Li C; London CA; Lin J; Houghton PJ
PLoS One; 2012; 7(4):e35513. PubMed ID: 22530037
[TBL] [Abstract][Full Text] [Related]
6. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.
Lin L; Benson DM; DeAngelis S; Bakan CE; Li PK; Li C; Lin J
Int J Cancer; 2012 Mar; 130(6):1459-69. PubMed ID: 21520044
[TBL] [Abstract][Full Text] [Related]
7. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
Zuo M; Li C; Lin J; Javle M
Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
[TBL] [Abstract][Full Text] [Related]
8. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.
Fossey SL; Bear MD; Lin J; Li C; Schwartz EB; Li PK; Fuchs JR; Fenger J; Kisseberth WC; London CA
BMC Cancer; 2011 Mar; 11():112. PubMed ID: 21443800
[TBL] [Abstract][Full Text] [Related]
9. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma.
Yan J; Wang Q; Zou K; Wang L; Schwartz EB; Fuchs JR; Zheng Z; Wu J
Mol Med Rep; 2015 Jul; 12(1):498-502. PubMed ID: 25760445
[TBL] [Abstract][Full Text] [Related]
11. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
12. Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma.
Ji XL; He M
Aging (Albany NY); 2019 Aug; 11(15):5848-5863. PubMed ID: 31422383
[TBL] [Abstract][Full Text] [Related]
13. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.
Wang S; Wang Y; Huang Z; Wei H; Wang X; Shen R; Lan W; Zhong G; Lin J
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1670-1680. PubMed ID: 34693451
[TBL] [Abstract][Full Text] [Related]
14. Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo.
Mao M; Zhang T; Wang Z; Wang H; Xu J; Yin F; Wang G; Sun M; Wang Z; Hua Y; Cai Z
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1214-1225. PubMed ID: 30659925
[TBL] [Abstract][Full Text] [Related]
15. The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.
Ball S; Li C; Li PK; Lin J
PLoS One; 2011 Apr; 6(4):e18820. PubMed ID: 21526200
[TBL] [Abstract][Full Text] [Related]
16. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
Bill MA; Nicholas C; Mace TA; Etter JP; Li C; Schwartz EB; Fuchs JR; Young GS; Lin L; Lin J; He L; Phelps M; Li PK; Lesinski GB
PLoS One; 2012; 7(8):e40724. PubMed ID: 22899991
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
Abuzeid WM; Davis S; Tang AL; Saunders L; Brenner JC; Lin J; Fuchs JR; Light E; Bradford CR; Prince ME; Carey TE
Arch Otolaryngol Head Neck Surg; 2011 May; 137(5):499-507. PubMed ID: 21576562
[TBL] [Abstract][Full Text] [Related]
18. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
Lin L; Deangelis S; Foust E; Fuchs J; Li C; Li PK; Schwartz EB; Lesinski GB; Benson D; Lü J; Hoyt D; Lin J
Mol Cancer; 2010 Aug; 9():217. PubMed ID: 20712901
[TBL] [Abstract][Full Text] [Related]
19. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells.
Liu Y; Fuchs J; Li C; Lin J
Cell Cycle; 2010 Sep; 9(17):3423-7. PubMed ID: 20818158
[TBL] [Abstract][Full Text] [Related]
20. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
